RAAS in diabetic retinopathy: mechanisms and therapies

Area of Science:

• Ophthalmology
• Endocrinology
• Cardiovascular Research

Background:

• Diabetic retinopathy (DR) is a significant complication of diabetes mellitus.
• The renin-angiotensin-aldosterone system (RAAS) plays a role in DR pathophysiology.
• Angiotensin II (Ang II) overexpression, driven by RAAS upregulation, contributes to retinal damage.

Purpose of the Study:

• To review the current understanding of RAAS in diabetic retinopathy.
• To explore the pathological mechanisms linking RAAS to DR.
• To identify potential therapeutic targets within the RAAS pathway for DR treatment.

Main Methods:

• Literature review of studies on RAAS and diabetic retinopathy.
• Synthesis of information on RAAS components and their role in retinal pathology.
• Analysis of potential therapeutic strategies involving RAAS inhibition.

Main Results:

• RAAS upregulation and Ang II overexpression are implicated in DR.
• Ang II induces oxidative stress, inflammation, and angiogenesis in the retina.
• RAAS inhibitors, used for hypertension, show potential for DR treatment.

Conclusions:

• The RAAS is a key player in the development and progression of diabetic retinopathy.
• Targeting the RAAS presents a promising therapeutic avenue for DR.
• Further research is needed to elucidate the precise mechanisms and optimize RAAS-targeted therapies for DR.